1
|
Salvadori K, Churý M, Budka J, Harvalík J, Matějka P, Šimková L, Lhoták P. Chemoselective Electrochemical Cleavage of Sulfonimides as a Direct Way to Sulfonamides. J Org Chem 2024; 89:1425-1437. [PMID: 38198698 PMCID: PMC10845148 DOI: 10.1021/acs.joc.3c01932] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 11/18/2023] [Accepted: 12/28/2023] [Indexed: 01/12/2024]
Abstract
A new method for selective cleavage of sulfonimides into sulfonamides in high yields using a simple electrochemical approach is shown. As revealed by the electrochemical study, the aromatic sulfonimides can be selectively cleaved by electrolysis of the starting compound at a given potential (only -0.9 V vs SCE for the nosyl group). The high chemoselectivity was confirmed by preparative electrolysis, and the results were supported with DFT calculations of a set of substances bearing different sulfonimide functions. Moreover, various experimental setups together with other attempts to simplify the procedure were tested. Finally, the removal of the p-nosyl group from the corresponding sulfonimides proceeds smoothly regardless of the number of nosyl groups and the overall shape of the complex molecule. Thus, the method is interesting for use in the field of multifunctional molecules such as calix[n]arenes.
Collapse
Affiliation(s)
- Karolína Salvadori
- J.
Heyrovský Institute of Physical Chemistry of Czech Academy
of Sciences v.v.i., Dolejškova 2155/3, 182 23 Prague 8, Czech Republic
- Department
of Physical Chemistry, University of Chemistry
and Technology, Prague (UCTP), Technická 5, 166 28 Prague 6, Czech Republic
- Institute
of Chemical Process Fundamentals of Czech Academy of Sciences v.v.i., Rozvojová 135, 165 02 Prague 6, Czech Republic
| | - Michal Churý
- Department
of Organic Chemistry, UCTP, Technická 5, 166 28 Prague 6, Czech Republic
| | - Jan Budka
- Department
of Organic Chemistry, UCTP, Technická 5, 166 28 Prague 6, Czech Republic
| | - Jakub Harvalík
- Department
of Physical Chemistry, University of Chemistry
and Technology, Prague (UCTP), Technická 5, 166 28 Prague 6, Czech Republic
| | - Pavel Matějka
- Department
of Physical Chemistry, University of Chemistry
and Technology, Prague (UCTP), Technická 5, 166 28 Prague 6, Czech Republic
| | - Ludmila Šimková
- J.
Heyrovský Institute of Physical Chemistry of Czech Academy
of Sciences v.v.i., Dolejškova 2155/3, 182 23 Prague 8, Czech Republic
| | - Pavel Lhoták
- Department
of Organic Chemistry, UCTP, Technická 5, 166 28 Prague 6, Czech Republic
| |
Collapse
|
2
|
Liashuk OS, Andriashvili VA, Tolmachev AO, Grygorenko OO. Chemoselective Reactions of Functionalized Sulfonyl Halides. CHEM REC 2024; 24:e202300256. [PMID: 37823680 DOI: 10.1002/tcr.202300256] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 09/13/2023] [Indexed: 10/13/2023]
Abstract
Chemoselective transformations of functionalized sulfonyl fluorides and chlorides are surveyed comprehensively. It is shown that sulfonyl fluorides provide an excellent selectivity control in their reactions. Thus, numerous conditions are tolerated by the SO2 F group - from amide and ester formation to directed ortho-lithiation and transition-metal-catalyzed cross-couplings. Meanwhile, sulfur (VI) fluoride exchange (SuFEx) is also compatible with numerous functional groups, thus confirming its title of "another click reaction". On the contrary, with a few exceptions, most transformations of functionalized sulfonyl chlorides typically occur at the SO2 Cl moiety.
Collapse
Affiliation(s)
- Oleksandr S Liashuk
- Enamine Ltd. (www.enamine.net), Winston Churchill Street 78, Kyїv, 02094, Ukraine
- Taras Shevchenko National University of Kyiv, Volodymyrska Street 60, Kyїv, 01601, Ukraine
| | - Vladyslav A Andriashvili
- Enamine Ltd. (www.enamine.net), Winston Churchill Street 78, Kyїv, 02094, Ukraine
- Taras Shevchenko National University of Kyiv, Volodymyrska Street 60, Kyїv, 01601, Ukraine
| | - Andriy O Tolmachev
- Enamine Ltd. (www.enamine.net), Winston Churchill Street 78, Kyїv, 02094, Ukraine
- Taras Shevchenko National University of Kyiv, Volodymyrska Street 60, Kyїv, 01601, Ukraine
| | - Oleksandr O Grygorenko
- Enamine Ltd. (www.enamine.net), Winston Churchill Street 78, Kyїv, 02094, Ukraine
- Taras Shevchenko National University of Kyiv, Volodymyrska Street 60, Kyїv, 01601, Ukraine
| |
Collapse
|
3
|
Ahmed-Belkacem R, Hausdorff M, Delpal A, Sutto-Ortiz P, Colmant AMG, Touret F, Ogando NS, Snijder EJ, Canard B, Coutard B, Vasseur JJ, Decroly E, Debart F. Potent Inhibition of SARS-CoV-2 nsp14 N7-Methyltransferase by Sulfonamide-Based Bisubstrate Analogues. J Med Chem 2022; 65:6231-6249. [PMID: 35439007 PMCID: PMC9045040 DOI: 10.1021/acs.jmedchem.2c00120] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2022] [Indexed: 12/15/2022]
Abstract
Enzymes involved in RNA capping of SARS-CoV-2 are essential for the stability of viral RNA, translation of mRNAs, and virus evasion from innate immunity, making them attractive targets for antiviral agents. In this work, we focused on the design and synthesis of nucleoside-derived inhibitors against the SARS-CoV-2 nsp14 (N7-guanine)-methyltransferase (N7-MTase) that catalyzes the transfer of the methyl group from the S-adenosyl-l-methionine (SAM) cofactor to the N7-guanosine cap. Seven compounds out of 39 SAM analogues showed remarkable double-digit nanomolar inhibitory activity against the N7-MTase nsp14. Molecular docking supported the structure-activity relationships of these inhibitors and a bisubstrate-based mechanism of action. The three most potent inhibitors significantly stabilized nsp14 (ΔTm ≈ 11 °C), and the best inhibitor demonstrated high selectivity for nsp14 over human RNA N7-MTase.
Collapse
Affiliation(s)
| | - Marcel Hausdorff
- IBMM,
University of Montpellier, CNRS, ENSCM, 34293 Montpellier, cedex 5, France
| | - Adrien Delpal
- AFMB,
University of Aix-Marseille, CNRS, 13288 Marseille, cedex 9, France
| | | | - Agathe M. G. Colmant
- IHU
Méditerranée Infection, Unité Virus Emergents, University of Aix-Marseille, IRD 190, INSERM 1207, 13005 Marseille, France
| | - Franck Touret
- IHU
Méditerranée Infection, Unité Virus Emergents, University of Aix-Marseille, IRD 190, INSERM 1207, 13005 Marseille, France
| | - Natacha S. Ogando
- Department
of Medical Microbiology, Leiden University
Medical Center, 2333 ZA Leiden, The Netherlands
| | - Eric J. Snijder
- Department
of Medical Microbiology, Leiden University
Medical Center, 2333 ZA Leiden, The Netherlands
| | - Bruno Canard
- AFMB,
University of Aix-Marseille, CNRS, 13288 Marseille, cedex 9, France
| | - Bruno Coutard
- IHU
Méditerranée Infection, Unité Virus Emergents, University of Aix-Marseille, IRD 190, INSERM 1207, 13005 Marseille, France
| | - Jean-Jacques Vasseur
- IBMM,
University of Montpellier, CNRS, ENSCM, 34293 Montpellier, cedex 5, France
| | - Etienne Decroly
- AFMB,
University of Aix-Marseille, CNRS, 13288 Marseille, cedex 9, France
| | - Françoise Debart
- IBMM,
University of Montpellier, CNRS, ENSCM, 34293 Montpellier, cedex 5, France
| |
Collapse
|
4
|
Sulfamide-substituted-BODIPY based fluorescence drugs: Synthesis, spectral characteristics, molecular docking, and bioactivity. ARAB J CHEM 2021. [DOI: 10.1016/j.arabjc.2021.103395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
5
|
Mitochondria-dependent synthetic small-molecule vaccine adjuvants for influenza virus infection. Proc Natl Acad Sci U S A 2021; 118:2025718118. [PMID: 34078669 DOI: 10.1073/pnas.2025718118] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Vaccine adjuvants enhance and prolong pathogen-specific protective immune responses. Recent reports indicate that host factors-such as aging, pregnancy, and genetic polymorphisms-influence efficacies of vaccines adjuvanted with Toll-like receptor (TLR) or known pattern-recognition receptor (PRR) agonists. Although PRR independent adjuvants (e.g., oil-in-water emulsion and saponin) are emerging, these adjuvants induce some local and systemic reactogenicity. Hence, new TLR and PRR-independent adjuvants that provide greater potency alone or in combination without compromising safety are highly desired. Previous cell-based high-throughput screenings yielded a small molecule 81 [N-(4-chloro-2,5-dimethoxyphenyl)-4-ethoxybenzenesulfonamide], which enhanced lipopolysaccharide-induced NF-κB and type I interferon signaling in reporter assays. Here compound 81 activated innate immunity in primary human peripheral blood mononuclear cells and murine bone marrow-derived dendritic cells (BMDCs). The innate immune activation by 81 was independent of TLRs and other PRRs and was significantly reduced in mitochondrial antiviral-signaling protein (MAVS)-deficient BMDCs. Compound 81 activities were mediated by mitochondrial dysfunction as mitophagy inducers and a mitochondria specific antioxidant significantly inhibited cytokine induction by 81. Both compound 81 and a derivative obtained via structure-activity relationship studies, 2F52 [N-benzyl-N-(4-chloro-2,5-dimethoxyphenyl)-4-ethoxybenzenesulfonamide] modestly increased mitochondrial reactive oxygen species and induced the aggregation of MAVS. Neither 81 nor 2F52 injected as adjuvants caused local or systemic toxicity in mice at effective concentrations for vaccination. Furthermore, vaccination with inactivated influenza virus adjuvanted with 2F52 demonstrated protective effects in a murine lethal virus challenge study. As an unconventional and safe adjuvant that does not require known PRRs, compound 2F52 could be a useful addition to vaccines.
Collapse
|
6
|
Shukla NM, Chan M, Lao FS, Chu PJ, Belsuzarri M, Yao S, Nan J, Sato-Kaneko F, Saito T, Hayashi T, Corr M, Carson DA, Cottam HB. Structure-activity relationship studies in substituted sulfamoyl benzamidothiazoles that prolong NF-κB activation. Bioorg Med Chem 2021; 43:116242. [PMID: 34274759 DOI: 10.1016/j.bmc.2021.116242] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 05/24/2021] [Accepted: 05/25/2021] [Indexed: 12/19/2022]
Abstract
In the face of emerging infectious diseases, there remains an unmet need for vaccine development where adjuvants that enhance immune responses to pathogenic antigens are highly desired. Using high-throughput screens with a cell-based nuclear factor κB (NF-κB) reporter assay, we identified a sulfamoyl benzamidothiazole bearing compound 1 that demonstrated a sustained activation of NF-κB after a primary stimulus with a Toll-like receptor (TLR)-4 agonist, lipopolysaccharide (LPS). Here, we explore systematic structure-activity relationship (SAR) studies on compound 1 that indicated the sites on the scaffold that tolerated modification and yielded more potent compounds compared to 1. The selected analogs enhanced release of immunostimulatory cytokines in the human monocytic cell line THP-1 cells and murine primary dendritic cells. In murine vaccination studies, select compounds were used as co-adjuvants in combination with the Food and Drug Administration approved TLR-4 agonistic adjuvant, monophosphoryl lipid A (MPLA) that showed significant enhancement in antigen-specific antibody titers compared to MPLA alone. Additionally, our SAR studies led to identification of a photoaffinity probe which will aid the target identification and mechanism of action studies in the future.
Collapse
Affiliation(s)
- Nikunj M Shukla
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA.
| | - Michael Chan
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Fitzgerald S Lao
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Paul J Chu
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Masiel Belsuzarri
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Shiyin Yao
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Jason Nan
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Fumi Sato-Kaneko
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Tetsuya Saito
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Tomoko Hayashi
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Maripat Corr
- Department of Medicine, University of California San Diego, La Jolla, CA 92093-0656, USA
| | - Dennis A Carson
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| | - Howard B Cottam
- Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0809, USA
| |
Collapse
|
7
|
Shpigelman J, Lao FS, Yao S, Li C, Saito T, Sato-Kaneko F, Nolan JP, Shukla NM, Pu M, Messer K, Cottam HB, Carson DA, Corr M, Hayashi T. Generation and Application of a Reporter Cell Line for the Quantitative Screen of Extracellular Vesicle Release. Front Pharmacol 2021; 12:668609. [PMID: 33935791 PMCID: PMC8085554 DOI: 10.3389/fphar.2021.668609] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Accepted: 03/30/2021] [Indexed: 12/18/2022] Open
Abstract
Extracellular vesicles (EVs) are identified as mediators of intercellular communication and cellular regulation. In the immune system, EVs play a role in antigen presentation as a part of cellular communication. To enable drug discovery and characterization of compounds that affect EV biogenesis, function, and release in immune cells, we developed and characterized a reporter cell line that allows the quantitation of EVs shed into culture media in phenotypic high-throughput screen (HTS) format. Tetraspanins CD63 and CD9 were previously reported to be enriched in EVs; hence, a construct with dual reporters consisting of CD63-Turbo-luciferase (Tluc) and CD9-Emerald green fluorescent protein (EmGFP) was engineered. This construct was transduced into the human monocytic leukemia cell line, THP-1. Cells expressing the highest EmGFP were sorted by flow cytometry as single cell, and clonal pools were expanded under antibiotic selection pressure. After four passages, the green fluorescence dimmed, and EV biogenesis was then tracked by luciferase activity in culture supernatants. The Tluc activities of EVs shed from CD63Tluc-CD9EmGFP reporter cells in the culture supernatant positively correlated with the concentrations of released EVs measured by nanoparticle tracking analysis. To examine the potential for use in HTS, we first miniaturized the assay into a robotic 384-well plate format. A 2210 commercial compound library (Maybridge) was then screened twice on separate days, for the induction of extracellular luciferase activity. The screening data showed high reproducibility on days 1 and 2 (78.6%), a wide signal window, and an excellent Z′ factor (average of 2-day screen, 0.54). One hundred eighty-seven compounds showed a response ratio that was 3SD above the negative controls in both day 1 and 2 screens and were considered as hit candidates (approximately 10%). Twenty-two out of 40 re-tested compounds were validated. These results indicate that the performance of CD63Tluc-CD9EmGFP reporter cells is reliable, reproducible, robust, and feasible for HTS of compounds that regulate EV release by the immune cells.
Collapse
Affiliation(s)
- Jonathan Shpigelman
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
| | - Fitzgerald S Lao
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
| | - Shiyin Yao
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
| | - Chenyang Li
- School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China
| | - Tetsuya Saito
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States.,Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Fumi Sato-Kaneko
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
| | - John P Nolan
- Scintillon Institute, San Diego, CA, United States
| | - Nikunj M Shukla
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
| | - Minya Pu
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States.,Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, United States
| | - Karen Messer
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States.,Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, United States
| | - Howard B Cottam
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
| | - Dennis A Carson
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
| | - Maripat Corr
- Department of Medicine, University of California, San Diego, La Jolla, CA, United States
| | - Tomoko Hayashi
- Moores Cancer Center, University of California, San Diego, La Jolla, CA, United States
| |
Collapse
|